All In Biotech

Drug Trial Radar · NCT00326898

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,943 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,943

Actual

Start

Apr 24, 2006

Primary completion

Aug 27, 2015

Study completion Sep 1, 2021

Sponsor

Sponsor type
NIH
Collaborators
Cancer and Leukemia Group B; NCIC Clinical Trials Group; SWOG Cancer Research Network
First posted
May 17, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sunitinib malate is more effective than sorafenib tosylate or placebo in treating kidney cancer.

Conditions

  • Clear Cell Renal Cell Carcinoma
  • Stage I Renal Cell Cancer AJCC v6 and v7
  • Stage II Renal Cell Cancer AJCC v7
  • Stage III Renal Cell Cancer AJCC v7

Interventions

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • PlaceboOther

    Given PO

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Sorafenib TosylateDrug

    Given PO

  • Sunitinib MalateDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free Survival (DFS)Time frame: Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry

Locations

987 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Clearview Cancer Institute

    Huntsville, Alabama

  • Mobile Infirmary Medical Center

    Mobile, Alabama

  • Providence Hospital

    Mobile, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Banner Thunderbird Medical Center

    Glendale, Arizona

  • Banner-University Medical Center Phoenix

    Phoenix, Arizona

  • Western Regional CCOP

    Phoenix, Arizona

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • Sparks Regional Medical Center

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Highlands Oncology Group-Rogers

    Rogers, Arkansas

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Valley Medical Oncology Consultants-Castro Valley

    Castro Valley, California

  • John Muir Medical Center-Concord Campus

    Concord, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Valley Medical Oncology Consultants-Fremont

    Fremont, California

  • Washington Hospital

    Fremont, California

  • Saint Jude Medical Center

    Fullerton, California

  • Glendale Memorial Hospital and Health Center

    Glendale, California

  • Marin Cancer Care Inc

    Greenbrae, California

  • Marin General Hospital

    Greenbrae, California

  • Saint Rose Hospital

    Hayward, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Veterans Affairs Loma Linda Healthcare System

    Loma Linda, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Memorial Medical Center

    Modesto, California

  • Community Hospital of Monterey Peninsula

    Monterey, California

Showing 40 of 987 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.